Form 4: Merus Director Victor Sandor Cashes Out Options

Merus N.V. Director Victor Sandor received cash for his share options following Genmab's tender offer at $97.00 per share.

Summary

• Merus N.V. Director Victor Sandor reported changes in beneficial ownership related to a tender offer.
• Genmab A/S and its wholly owned subsidiary, Genmab Holding II B.V., commenced a tender offer for all issued and outstanding common shares of Merus N.V.
• The tender offer consideration was a cash payment of $97.00 per share, without interest and less applicable withholding taxes.
• On December 12, 2025, the Purchaser accepted all validly tendered shares.
• Mr. Sandor's share options were cancelled pursuant to the Transaction Agreement in exchange for cash.
• The cash payment for each option was calculated as the product of (i) the amount by which the $97.00 Offer Consideration exceeds the applicable exercise price per share of such option and (ii) the aggregate number of shares underlying such option, net of applicable withholding tax and other deductions.
• A total of 84,806 common shares underlying seven different share option grants were cancelled, with exercise prices ranging from $14.39 to $48.73.

Sentiment

Score: 9

Explanation: The filing details a highly positive financial event for the reporting person, who realized significant cash gains from the cancellation of options due to a tender offer at a premium price.

Positives

• Director Victor Sandor realized significant cash value from his share options due to the tender offer.
• The tender offer provided a clear exit strategy and immediate liquidity for option holders.
• The offer price of $97.00 per share is substantially higher than all listed option exercise prices, indicating a profitable outcome for the option holder.

Negatives

• The cancellation of options means the reporting person no longer holds potential future equity upside in Merus N.V. through these specific instruments.

Future Outlook

The filing indicates the completion of a tender offer, suggesting Merus N.V. is likely to be acquired by Genmab, which will significantly alter its future operational and financial structure as an independent entity.

Industry Context

This transaction reflects a consolidation trend within the biotechnology or pharmaceutical sector, where larger entities like Genmab acquire companies with promising assets or technologies, such as Merus N.V., to expand their pipelines or market share. Such acquisitions often provide liquidity events for shareholders and employees of the acquired company.

Stakeholder Impact

• Shareholders: Shareholders who tendered their shares received $97.00 per share in cash, providing a liquidity event.
• Option Holders (like Victor Sandor): Realized significant cash value from their options, effectively monetizing their equity compensation.
• Employees: While not explicitly stated, a tender offer and acquisition often lead to changes in employee structure, compensation, and benefits.
• Merus N.V. as an entity: Will become a subsidiary of Genmab, losing its independent public company status.

Next Steps

• Payment of the Offer Consideration to shareholders as soon as practicable following the Acceptance Time (December 12, 2025).
• Further integration or operational changes for Merus N.V. under Genmab's ownership.

Key Dates

Keywords

Merus N.V., MRUS, Genmab, Tender Offer, Share Options, Beneficial Ownership, SEC Form 4, Director Transaction, Equity Compensation, Acquisition